Related Experiment Video
Updated: Aug 16, 2026

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals
Published on: January 5, 2016
N-acetyl-cysteine in the therapy of HIV-positive patients
1Division of Immunochemistry, Deutsches Krebforschungszentrum, Heidelberg, Germany. w.droege@dkfz-heidelberg.de
Abstract:
Randomly selected asymptomatic HIV-positive persons reveal, on average, a massive daily loss of sulphur, which appears to represent in first approximation the mean loss throughout the asymptomatic stage, and may explain the widely observed decrease in cyst(e)ine and glutathione levels. This sulphur loss is reasonably expected to lead, within a few years, to a life-threatening condition and may, therefore, contribute decisively to disease progression. Importantly, the rate of sulphur loss is not ameliorated by highly active antiretroviral therapy and may contribute to antiretroviral treatment failure. Several clinical trials on N-acetyl-cysteine treatment of HIV-positive patients have revealed various therapeutic effects, but did not meet the rigorous standards for approval by the health authorities.
Related Concept Videos
Retrovirus Life Cycles
Alzheimer's Disease: Treatment
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Cryptococcal Meningitis
Antiviral Nucleoside Inhibitors

